171 related articles for article (PubMed ID: 2474101)
1. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.
Erman A; Winkler J; Chen-Gal B; Rabinov M; Zelykovski A; Tadjer S; Shmueli J; Levi E; Akbary A; Rosenfeld JB
J Hypertens; 1991 Nov; 9(11):1057-62. PubMed ID: 1661764
[TBL] [Abstract][Full Text] [Related]
3. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
Becker RH; Baldes L; Treudler M
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
[TBL] [Abstract][Full Text] [Related]
4. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
5. Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
Debusmann ER; Pujadas JO; Lahn W; Irmisch R; Jané F; Kuan TS; Mora J; Walter U; Eckert HG; Hajdú P
Am J Cardiol; 1987 Apr; 59(10):70D-78D. PubMed ID: 3034037
[TBL] [Abstract][Full Text] [Related]
6. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
[TBL] [Abstract][Full Text] [Related]
7. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
9. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
10. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.
Kindler J; Schunkert H; Gassmann M; Lahn W; Irmisch R; Debusmann ER; Ocón-Pujadas J; Ritz E; Sieberth HG
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S55-8. PubMed ID: 2474105
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of ramipril in renal failure.
Aurell M; Delin K; Herlitz H; Ljungman S; Witte PU; Irmisch R
Am J Cardiol; 1987 Apr; 59(10):65D-69D. PubMed ID: 3034036
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients.
Gilchrist WJ; Beard K; Manhem P; Thomas EM; Robertson JI; Ball SG
Am J Cardiol; 1987 Apr; 59(10):28D-32D. PubMed ID: 3034029
[TBL] [Abstract][Full Text] [Related]
15. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
[TBL] [Abstract][Full Text] [Related]
16. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril.
Sugimoto K; Kumagai Y; Tateishi T; Seguchi H; Ebihara A
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S40-4. PubMed ID: 2474100
[TBL] [Abstract][Full Text] [Related]
17. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four hour changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE498) in normal man.
Malatino LS; Manhem P; Ball SG; Leckie BJ; Morton JJ; Murray GD; Robertson JI
J Clin Hypertens; 1986 Sep; 2(3):231-7. PubMed ID: 3023553
[TBL] [Abstract][Full Text] [Related]
19. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.
Düsing R; Kayser G; Wagner S; Scherf H; Glänzer K; Predel HG; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):50D-54D. PubMed ID: 3034033
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.
MacDonald NJ; Hughes DM; Lees KR; Reid JL
Br J Clin Pharmacol; 1990 Jul; 30(1):107-13. PubMed ID: 2202384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
